| Name | Title | Contact Details |
|---|
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
AmbryX Biotechnology is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Epeius Biotechnologies is a San Marino, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Controle Analytique Inc is a Thetford Mines, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Bayhill Therapeutics is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.